Abstract
The impact of Parkinson’s disease (PD) on workforce participation has received little attention even though demographic, lifestyle, and political changes together will result in an increased burden of PD on the working-age population. In this study, we investigate workforce survival after a PD diagnosis, as well as what demographic factors that are associated with workforce survival. As an exploratory outcome, we investigate workforce survival in persons with and without device-aided treatment (DAT). This is a nested case-cohort study based on Swedish national data from 2001–2016. Controls were matched on year of birth, sex, and municipality of residence. The used registers contain data on demographics, social insurance, in- and outpatient visits, filled drug prescriptions, and cause of death on the person-level. A total of 4781 persons with PD and 23,905 controls were included. The median survival until all-cause workforce exit was 43 months among persons that were workforce-active at the time of PD diagnosis, compared to 66 months in non-PD controls. Being female, ≥50 years old at diagnosis, or having a lower education were contributing factors to health-related workforce exit. Persons receiving DAT during follow-up exhibited shorter workforce survival than controls. However, this needs further investigation, particularly as patients have generally already left the workforce at the time for start of DAT. It is evident that PD has grave negative effects on workforce participation. Thus, supportive measures need to start at an early stage after diagnosis, and the development of new interventions is urgently needed.
Similar content being viewed by others
Introduction
The effects of Parkinson’s disease (PD) on working ability have received unjustifiably little attention1. Just as extending working life participation beyond one’s capacity leads to dissatisfaction, so does forced workforce exit2. Improved general health predisposes for later retirement at the population level3, which paradoxically increases the risk of interference of PD on the ability to work4,5. It is evident from PD-related research on workforce participation that not only worsened manual dexterity, but also anxiety, sleeping difficulties, and difficulties eating or drinking are factors that contribute to leaving work early6. The results point to fatigue7, rigidity/bradykinesia, and stress intolerance as particularly detrimental to the working ability2. Together, this complex constellation of symptoms contribute to the fact that among persons with PD, employment has historically been rare beyond 10 years after diagnosis1.
Previous studies on workforce participation and PD have mainly included small samples and used questionnaire data1,8,9. We wanted to employ large-scale real-world data to chart workforce participation after a PD diagnosis in the 21st century. The infrastructure for register studies is strong in the Nordic countries. Although this infrastructure has been used to show that the sickness absence and healthcare spending is increased already prior to a PD diagnosis10,11, its potential is under-utilized in relation to the scarce knowledge concerning working ability and PD.
Evidence of beneficial effects on workforce participation is an important justification of potential new therapeutic options for PD, such as stem cell therapy12. Exploratory studies on the current generation of device-aided treatment (deep brain stimulation, levodopa-carbidopa intestinal gel, or subcutaneous apomorphine infusion; DAT) indicate that there are positive effects on the working ability of persons with PD and motor complications13,14,15.
The primary objective of our study was to determine the time to workforce exit in persons diagnosed with PD in the total Swedish population. The second objective was to explore what factors that are associated with workforce exit in PD patients. A third aim was to investigate how DAT affects workforce participation in PD.
Results
Cases and controls
A total of 4,781 cases diagnosed with PD and 23,905 controls were identified from the base population during the ten-year inclusion period (Table 1). A majority of persons included were male (59%) and the median age was 59 years. PD cases were less likely to be workforce active at the time of diagnosis than matched controls (PD, control, χ2 test, [64.3%, 73.9%, P < 0.001]), less likely to emigrate during the follow-up (0.4%, 0.8%, P = 0.001), more likely to die during the follow-up (20.5%, 7.6%, P < 0.001), and had slightly longer education (P < 0.001).
Workforce exit
Workforce exit was more common among PD cases than among controls at all time intervals in relation to the PD diagnosis, except in the age group 60 years and older (Table 2). In that age group, there were no significant differences in workforce participation between PD cases and controls beyond five years after diagnosis.
The median survival until all-cause workforce exit was 43.0 (95% CI: 40.7–45.3) months among persons with PD that were workforce-active at the time of diagnosis, which was significantly shorter than the 66.0 (95% CI: 64.3–67.7) months in the non-PD control group (P < 0.001, Fig. 1).
There were no significant differences between sexes in the time to all-cause workforce exit after diagnosis within neither the PD (P = 0.545) nor the control (P = 0.433) group (Fig. 2a). Workforce-active persons with PD and higher education exhibited a significantly longer median survival until all-cause workforce exit (52.0 [95% CI: 48.0–55.9]) than persons with PD and lower education (38.0 [95% CI: 35.2–40.8], P < 0.001) and controls (P < 0.001; Fig. 2b).
The median survival until all-cause workforce exit was shorter among persons with PD than among controls at all age intervals (all P < 0.001; Fig. 3a–c). The median survival until all-cause workforce exit ranged from 147.0 (95% CI: 133.4–160.6) months in workforce active persons diagnosed before age 50 (Fig. 3a) to 19.0 (95% CI: 17.9–20.1) months in workforce active persons diagnosed at age 60 years or older (Fig. 3c).
The median survival until health-related workforce exit was significantly shorter in workforce-active persons with PD diagnosed before an age of 60 years (123.0 months [95% CI: 113.3–132.7]) compared to controls (P < 0.001; Fig. 4). The median survival until health-related workforce exit differed significantly between men and women with PD (P = 0.031; Fig. 5a), as well as between persons diagnosed earlier than an age of 50 years and between ages 50–59 years (P < 0.001; Fig. 5b). Furthermore, there were significant differences in the median survival until health-related workforce exit when separated on the level of education in both the PD (P < 0.001) and the control group (P < 0.001; Fig. 5c).
Using a Cox proportional hazards model, it was found that being 50 years or older at diagnosis (hazard ratio [HR]: 1.56 [95% CI: 1.31–1.85]; P < 0.001), having a lower education (HR: 1.54 [95% CI: 1.31–1.80]; P < 0.001), and being female (HR: 1.21 [95% CI: 1.05–1.41]; P = 0.011) were significant contributing factors to health-related workforce exit in persons with PD (Table 3).
There was a significant difference in the workforce survival distribution between persons with PD who did not receive DAT during follow-up compared to persons with PD who did (P = 0.012; Fig. 6). The median survival until health-related workforce exit was 64.0 (95% CI: 59.1–68.9) months in persons with no DAT during follow-up and 57 (95% CI: 51.3–62.7) months in persons with initiation of DAT during follow-up. However, persons who received DAT generally did so after they had already left the workforce as the median time from diagnosis to DAT was 89 (1st–3rd quartile: 66–113.5) months.
Discussion
To our knowledge, this is the largest study on workforce participation in PD to date. The primary finding is that the median workforce survival among workforce active persons receiving a PD diagnosis was about two years shorter than in age- and sex-matched controls (43 months compared to 66 months). Among persons diagnosed with PD during a ten-year period, 33.5% had stopped working at diagnosis, 76.7% within 5 years, and 90.9% within 10 years. We also found that, on the group level, persons that were male, with post-secondary education or higher, and an earlier age of PD diagnosis stayed at work longer.
Previous studies have found the time to loss of employment in workforce active persons with PD to be a median of 7 (95% CI: 4.8–9.2) years9, a median of 6 (95% CI: 5.4–6.6) years8, or a mean of 4.2 ± 4.4 years6. In our study, there were significant differences in median workforce survival depending on the age of diagnosis. For persons diagnosed before an age of 50 years, the median workforce survival was 147 months (Fig. 3A), while it was 19 months for those diagnosed after an age of 60 years (Fig. 3C). Although the prior studies are not dissimilar to our finding of a median survival of 43 months/3.6 years, the age of the study populations and national differences with regards to stipulated retirement age (65 years in Sweden at the time of the study) are likely to influence the time to loss of employment considerably. Nonetheless, for these reasons, comparisons of workforce survival in populations of persons with PD must be made with considerable caution and should preferably include references to matched non-PD populations.
We show that the workforce participation in the PD case group was reduced significantly already at the time of diagnosis in all age groups (Table 2). This is in line with previous studies showing increased prediagnostic morbidity16,17, unemployment, healthcare spending10, and sick-leave in persons later diagnosed with PD11. The established symptoms of prodromal PD—such as rapid eye movement (REM) sleep behavior disorder, autonomic dysfunction, depression, and mild motor signs18—can largely explain the increased prediagnostic risk for falls16,19, musculoskeletal disorders11, constipation, urinary dysfunction, and fatigue seen in previous studies17. The National Patient Register does not include primary care visits, but persons in Sweden seeking primary care with a suspected movement disorder are typically referred to a neurologist for diagnosis. We, therefore, think that the considerable majority of newly diagnosed PD patients in the studied age span were included in this study. However, due to the nature of both the healthcare system and the progression of PD, there can be a delay between the first appearances of clinical symptoms to a diagnosis. Together with the potential misclassification of other illness as PD, this may have contributed to the reduced workforce participation already at diagnosis in the PD case group.
We found that higher education is associated with longer workforce survival among persons with PD. Potential explanations for this finding are that education is a proxy for having a higher socioeconomic status and/or cognitive reserve20. Persons with higher socioeconomic status generally have more influence over their workday and a stronger connection between effort and reward, which may reduce the risk for job dissatisfaction. Furthermore, both declining health and job dissatisfaction increase the probability for job loss in workers: self-perceived healthy workers who are dissatisfied with their job have a six-fold increase in the risk for health-related job loss21. Persons who already rate their health as poor have a higher risk for disability pension, unemployment, and early retirement, while chronic disease and mental health problems increase the risk for disability pension and unemployment, but not early retirement22. Education, the type of occupation, and cognitively stimulating leisure activities are markers of a higher cognitive reserve23,24, which may help protect against a decline in executive and memory function that can be detrimental for the work ability20.
The finding that persons with PD receiving DAT during follow-up had significantly shorter workforce survival than those that did not (Fig. 6) contrasts previous studies indicating that DAT might help sustain working ability14,15 and performance of daily activities13 in PD. However, DATs are typically initiated during mid-to-advanced stages of PD, at which point a significant portion of working-age persons with PD have already left the workforce1. Our finding that the median time from diagnosis to initiation of DAT exceeds the median workforce survival in the DAT group (89 versus 57 months) underscores this problem.
The large number of workforce active persons with PD included is a unique strength of this study. However, the study has several limitations that need to be considered in the interpretation of the results. Firstly, the percentage of misclassified PD in the National Inpatient Register is not known, but it is likely that the case group included a minority of persons with atypical parkinsonism or other movement disorders. This is also supported by the surprisingly large proportion of deaths during follow-up in the case group, which could be the result of a misclassification of persons with more rapidly progressing movement disorders than PD. The overall positive predictive value of the Inpatient Register has been shown to be between 85–95% depending on the diagnosis25. Secondly, any misclassification of younger persons is likely to result in larger discrepancies as the expected workforce survival is long. Furthermore, the data we had access to lack information on many of the disease-specific characteristics that are likely to influence workforce survival in PD. This information could for example have improved the accuracy of the matching between persons with PD and either DAT or not.
Persons with young- or early-onset PD are typically progressing at a slower rate than those with later onset and have been shown to exhibit distinct biochemical features26,27,28. Although the time to loss of employment is longer in persons with earlier PD onset, so is the time of lost employment and the amount of lifetime earnings loss29. The slower disease progression and more future workforce participation and income at risk make persons with early-to-mid PD onset ideal for future interventions aiming to improve workforce participation after a PD diagnosis. However, the increased probability for underlying predisposing mutations in younger persons with PD must be considered as this may affect the generalizability of findings.
This study was based on the total Swedish population and just as for most previous studies on workforce participation in PD, the unique setup of a single country’s healthcare and social security system may affect the generalizability of the findings. Nevertheless, some of the findings are of particular interest. Workforce participation is reduced already at the time of a PD diagnosis and continues to decline during the course of the disease. The effect of DAT on working ability in PD is still not clear and, according to current routines, DATs are often introduced at a stage in the disease when many have already stopped working. Studies on the effect of DAT on the work ability of workforce active persons with PD are warranted. Supportive measures intended to facilitate workforce participation are needed shortly after the PD diagnosis has been established and structured interventions aiming to improve workforce participation for this population are warranted.
Methods
Study design
This was a nested case cohort study. The base population used for the study was the total Swedish population (which reached 10 million in January 2017). Cases were identified from the Swedish National Patient Register and controls from the Total Population Register at Statistics Sweden. Individual-level endpoint and exposure data were collected from additional national registers. The primary endpoint measure was all-cause workforce exit. Health-related workforce exit was used as secondary outcome measure.
Data sources
Data were retrieved from registers held by the Swedish National Board of Health and Welfare and Statistics Sweden. Data from the National Patient Register, the National Prescribed Drug Register, the Cause of Death Register, and the Longitudinal Integrated Database for Health Insurance and Labor Market Studies (LISA) were merged into a dedicated study database for the analyses.
The National Patient Register contains patient, geographical, administrative, and medical data from inpatient (since the 1960’s) and outpatient (since 2001) specialist healthcare provided by both private and public caregivers in Sweden. Primary care visits are not included in the register. Individual-level data on the first occurrence of a PD diagnosis (for cases) and deep-brain stimulation surgery were added to the study database for both cases and controls.
The National Prescribed Drug Register contains patient, product, and prescription data, costs, and prescriber information on all prescribed drugs dispensed at pharmacies in Sweden. The register was established in July 2005. The date of first prescription of drugs commonly used in the treatment of PD was added to the study database for both cases and controls.
Established in 1961, the Cause of Death Register is a compilation of the cause-of-death certificates that must be sent to the National Board of Health and Welfare within three weeks following the death of a person in Sweden. The certificate states the cause of death and co-morbidities or circumstances contributing to the death according to the International Statistical Classification of Diseases and Related Problems (ICD-10) system. The date of death was added to the study database.
LISA was established in 1990 and contains information on demographics, education and training, employment and unemployment, income, and social insurance. Persons 15 years or older that were registered in the Swedish population on December 31st of each year are included. LISA was the basis for sociodemographic and workforce-related information for cases and controls in the study database.
Study populations
From the base population, Swedish citizens aged 18–64 years residing in Sweden and receiving a first PD diagnosis in the National Patient Register during the years 2003–2012 were identified. Persons with a registered PD diagnosis during the years 2001–2002 and persons who immigrated to Sweden during 2001–2016 were excluded to increase the certainty of the date of diagnosis. The identified cases were initially matched in a 1:5 ratio to controls from the Swedish population using Statistics Sweden’s Total Population Register using the year of birth, sex, and municipality of residence at the time of diagnosis to form a primary case-control study population. Taking also workforce status at time of diagnosis into account, a second matching at a 1:4 ratio was made to form a secondary case-control study population for the survival analyses. In a third matching, non-PD controls, persons with PD and no DAT during follow-up, and persons with PD and DAT during follow-up were matched on age at diagnosis/matching (±1 year) and sex. Cases were not allowed to be used as controls prior to becoming a case and controls were allowed to be drawn only once. The last day of inclusion was December 31st 2012 and the end of follow-up was December 31st 2016.
Statistical analyses
The primary study population was presented using descriptive statistics. Differences between the PD cases and controls regarding age, sex, place of birth, medication, DAT during follow-up, workforce participation at diagnosis, death during follow-up, and emigration during follow-up were tested using χ2 or Mann–Whitney U tests depending on the type of data.
Individuals in the study populations were followed from the date of recording until workforce exit, death, emigration, or end of follow-up. Analyses of determinants of workforce exit were performed with workforce active cases matched at the time of inclusion to workforce active controls on age and sex. The Kaplan–Meier method was used to investigate the time to all-cause and health-related workforce exit among persons with PD and controls. All-cause workforce exit was defined as the first occurrence of either death, two successive years without information from employer on income, one year with ≥274 days of sickness pension, one year with full pension; two successive years with ≥274 days of sick pay, rehabilitation, or working injury compensation; or two successive years with ≥274 days of unemployment. Health-related workforce exit was defined as two successive years with ≥274 days of sick pay, rehabilitation, or working injury compensation; or one year with ≥274 days of sickness pension. The median survival was defined as the length of time from the point of diagnosis or matching to the point at which half of the persons originally at risk had reached the event. Log-rank tests were used to investigate differences in survival distribution.
A Cox proportional-hazards model was used to investigate associations between workforce survival time and age, sex, and educational level.
IBM SPSS version 27.0 was used for statistical analyses. P < 0.05 was considered statistically significant. Data were stored, handled, and analyzed according to the General Data Protection Regulation (GDPR) on the Lund University secure data management platform LUSEC.
Data availability
No additional data can be provided by the authors. Data from the named databases are available through request from the respective government agencies.
Code availability
The underlying code for this study is not publicly available but may be made available to qualified researchers on reasonable request to the corresponding author.
References
Koerts, J., Konig, M., Tucha, L. & Tucha, O. Working capacity of patients with Parkinson’s disease - a systematic review. Parkinsonism Relat. Disord. 27, 9–24 (2016).
Gustafsson, H., Nordstrom, P., Strahle, S. & Nordstrom, A. Parkinson’s disease: a population-based investigation of life satisfaction and employment. J. Rehabil. Med. 47, 45–51 (2015).
GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1859–1922 (2018).
Hirsch, L., Jette, N., Frolkis, A., Steeves, T. & Pringsheim, T. The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology 46, 292–300 (2016).
Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 8, S3–S8 (2018).
Collett, J. et al. Lost employment potential and supporting people with Parkinson’s to stay in work: insights from a Pan European cross-sectional survey. Disabil. Rehabil. 45, 832–839 (2022).
Martikainen, K. K., Luukkaala, T. H. & Marttila, R. J. Parkinson’s disease and working capacity. Mov. Disord. 21, 2187–2191 (2006).
Schrag, A. & Banks, P. Time of loss of employment in Parkinson’s disease. Mov. Disord. 21, 1839–1843 (2006).
Murphy, R., Tubridy, N., Kevelighan, H. & O’Riordan, S. Parkinson’s disease: how is employment affected? Ir. J. Med. Sci. 182, 415–419 (2013).
Jennum, P., Zoetmulder, M., Korbo, L. & Kjellberg, J. The health-related, social, and economic consequences of parkinsonism: a controlled national study. J. Neurol. 258, 1497–1506 (2011).
Timpka, J. et al. Reduced workforce participation 5 years prior to first Parkinson’s disease sick-leave. NPJ Parkinsons Dis. 4, 36 (2018).
Parmar, M., Grealish, S. & Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21, 103–115 (2020).
Sahlstrom, T. et al. Workforce participation and activities in Parkinson’s disease patients receiving device-aided therapy. Acta Neurol. Scand. 138, 78–84 (2018).
Deli, G. et al. Deep brain stimulation can preserve working status in Parkinson’s disease. Parkinsons Dis. 2015, 936865 (2015).
Stoker, V. et al. Deep brain stimulation impact on social and occupational functioning in parkinson’s disease with early motor complications. Mov. Disord. Clin. Pract. 7, 672–680 (2020).
Frandsen, R., Kjellberg, J., Ibsen, R. & Jennum, P. Morbidity in early Parkinson’s disease and prior to diagnosis. Brain Behav. 4, 446–452 (2014).
Schrag, A., Horsfall, L., Walters, K., Noyce, A. & Petersen, I. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 14, 57–64 (2015).
Berg, D. et al. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat. Rev. Neurol. 17, 349–361 (2021).
Nystrom, H., Nordstrom, A. & Nordstrom, P. Risk of injurious fall and hip fracture up to 26 y before the diagnosis of Parkinson disease: nested case-control studies in a nationwide cohort. PLoS Med 13, e1001954 (2016).
Loftus, A. M. et al. Cognitive reserve, executive function, and memory in Parkinsonas disease. Brain Sci. 11, 992 (2021).
D’Angelo, S. et al. How does job dissatisfaction interact with self-rated health in determining the risk of health-related job loss? Prospective findings from the Health and Employment After Fifty (HEAF) study. Occup. Environ. Med. 78, 36–42 (2021).
van Rijn, R. M., Robroek, S. J. W., Brouwer, S. & Burdorf, A. Influence of poor health on exit from paid employment: a systematic review. Occup. Environ. Med. 71, 295–301 (2014).
Greenberg, K. & Burgard, S. Cumulative employment intensity and complexity across the life course and cognitive function in later life among European women and men. Ann. Epidemiol. 58, 83–93 (2021).
Ihle, A. et al. The role of cognitive reserve accumulated in midlife for the relation between chronic diseases and cognitive decline in old age: a longitudinal follow-up across six years. Neuropsychologia 121, 37–46 (2018).
Ludvigsson, J. F. et al. External review and validation of the Swedish national inpatient register. BMC Public Health 11, 450 (2011).
Mehanna, R. & Jankovic, J. Young-onset Parkinson’s disease: its unique features and their impact on quality of life. Parkinsonism Relat. D 65, 39–48 (2019).
Ferguson, L. W., Rajput, A. H. & Rajput, A. Early-onset vs. late-onset Parkinson’s disease: a clinical-pathological study. Can. J. Neurol. Sci. 43, 113–119 (2016).
Schirinzi, T. et al. Young-onset and late-onset Parkinson’s disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiol. Aging 90, 119–124 (2020).
Johnson, S. et al. Early retirement and income loss in patients with early and advanced Parkinson’s disease. Appl. Health Econ. Health Policy 9, 367–376 (2011).
Acknowledgements
This investigator-initiated study was supported by AbbVie through a grant to Professor Per Odin. AbbVie reviewed the final draft prior to submission. The authors would like to thank MultiPark, the Strategic Research Area in neuroscience at Lund University; the Medical Faculty at Lund University, the Swedish Parkinson Academy, and the Swedish Parkinson Foundation for their support.
Funding
Open access funding provided by Lund University.
Author information
Authors and Affiliations
Contributions
J.T.: conception, organization, and execution of research project. Design, execution, review, and critique of statistical analyses. Writing of first draft, review, and critique of manuscript. Ö.D., M.H.N., S.I.: organization and execution of research project. Review and critique of statistical analyses. Review and critique of manuscript. P.O.: conception, organization, and execution of research project. Design, review, and critique of statistical analyses. Review and critique of manuscript.
Corresponding author
Ethics declarations
Ethical review
The study was approved by the Swedish Ethical Review Authority (Dnr: 2019-02820). No informed consent was collected from participants as it is not required by Swedish law for this type of study.
Competing interests
J.T. has received funding from the Swedish National Government and County Councils through the ALF agreement, the Swedish Parkinson Foundation, and the Elsa Schmitz Foundation, and has received compensation for consultancies from AbbVie, TransPerfect, and the Swedish National Board of Health and Welfare, as well as royalties from UNI-MED Verlag. Ö.D. has received funding from Faculty of Arts and Sciences, Linköping University. M.N. was funded by MultiPark, the Strategic Research Area in neuroscience at Lund University, Lund, Sweden. S.I. has received honoraria from Karolinska Institutet and Swedish Agency for Participation. She has received research funding from Ribbingska Foundation in Lund, Swedish Research Council; Swedish Research Council for Health, Working Life and Welfare (Forte); Swedish Research Council for Sustainable Development (Formas), NEURO Sweden, Family Kamprad Foundation, LMK Foundation, Lund University, Lund University Innovation System, Helsingborg City Competence Foundation. P.O. has received funding from AbbVie, Lund University Medical Faculty, MultiPark, the Swedish Parkinson Foundation, Region Skåne, and Åhlén Foundation. He has received honoraria for lectures and expert advice from AbbVie, Bial, Britannia, Ever Pharma, Global Kinetics, Lobsor, Nordic Infucare, Stada, and Zambon. He has received royalties from UNI-MED Verlag.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Timpka, J., Dahlström, Ö., Nilsson, M.H. et al. Time to workforce exit after a Parkinson’s disease diagnosis. npj Parkinsons Dis. 9, 72 (2023). https://doi.org/10.1038/s41531-023-00513-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41531-023-00513-0